Compare FULTP & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Fulton Financial Corporation Depositary Shares Each Representing a 1/40th Interest in a Share of Fixed Rate Non-Cumulative Perpetual Preferred Stock Series A
Current Price
| Metric | FULTP | SENS |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Industrial Machinery/Components |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 496.0M |
| IPO Year | 1995 | 2014 |
| Metric | FULTP | SENS |
|---|---|---|
| Price | $17.12 | $9.91 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $14.20 |
| AVG Volume (30 Days) | 7.2K | ★ 588.8K |
| Earning Date | N/A | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.48 | N/A |
| EPS | ★ 1.02 | N/A |
| Revenue | ★ $276,768,000.00 | $16,389,000.00 |
| Revenue This Year | N/A | $82.21 |
| Revenue Next Year | N/A | $55.63 |
| P/E Ratio | $17.03 | ★ N/A |
| Revenue Growth | N/A | ★ 19.85 |
| 52 Week Low | $17.21 | $0.41 |
| 52 Week High | $20.25 | $10.48 |
| Indicator | FULTP | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 32.42 | 63.39 |
| Support Level | N/A | $5.36 |
| Resistance Level | $18.01 | N/A |
| Average True Range (ATR) | 0.28 | 0.44 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 29.52 | 73.21 |
Fulton Financial Corp is a U.S.-based financial services holding company that operates in five states: Pennsylvania, Delaware, Maryland, New Jersey and Virginia. It offers a range of consumer and commercial banking products and services, such as checking and savings deposit products and loan products. It offers consumer and commercial banking products and services, as well as wealth management products and services. The bank derives its revenue from non-interest income, led by its Wealth Management division.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.